Fusion proteins containing recombinant cytotoxic rnases

Abstract

Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may lie used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.

1 - 19 . (canceled) 
     
     
         20 . A method of treating cancer, comprising administering to a human subject a therapeutically effective amount of an immunotoxin comprising:
 (a) a first fusion polypeptide, wherein said fusion polypeptide comprises a non-mammalian ribonuclease fused to a first immunoglobulin variable domain and   (b) a second polypeptide comprising a second immunoglobulin variable domain, wherein said first and second immunoglobulin variable domains comprise the CDRs of the immunoglobulin heavy and light chain of an antibody which together form an antigen binding site   wherein said non-mammalian ribonuclease is fused to the N-terminus of said first immunoglobulin variable domain, wherein said non-mammalian ribonuclease bears an N-terminal pyroglutamate residue, and wherein the first immunoglobulin variable domain is a light chain variable domain.   
     
     
         21 . The method according to  claim 20 , wherein said non-mammalian ribonuclease is ranpirnase or a conservatively modified variant thereof and wherein the immunotoxin is glycosylated. 
     
     
         22 . The method according to  claim 20 , wherein said non-mammalian ribonuclease is Rap (N69Q) ranpirnase. 
     
     
         23 . The method according to  claim 20 , wherein the antibody binds to an antigen selected from the group consisting of CD22, EGP-1, CD74, and CEA. 
     
     
         24 . The method according to  claim 20 , wherein the immunotoxin is glycosylated on the CH2 domain. 
     
     
         25 . The method according to  claim 20 , wherein the non-mammalian ribonuclease is from  Rana pipiens.    
     
     
         26 . The method according to  claim 20  wherein said variable domains are humanized or human domains. 
     
     
         27 . The method according to  claim 20 , wherein the non-mammalian ribonuclease is fused only to the N-terminus of said first immunoglobulin variable domain. 
     
     
         28 . The method according to  claim 20 , wherein the antibody is selected from the group consisting of hLL2, hRS7, hLL1 and hMN14, which bind CD22, EGP-1, CD74, and CEA, respectively. 
     
     
         29 . The method according to  claim 20 , wherein the antibody is hMN14, which binds CEA. 
     
     
         30 . The method according to  claim 20 , wherein the antibody is hLL1, which binds CD74. 
     
     
         31 . The method according to  claim 20 , wherein the antibody is hRS7, which binds EGP-1. 
     
     
         32 . The method according to  claim 20 , wherein the antibody is hLL2, which binds CD22. 
     
     
         33 . The method according to  claim 20 , wherein the cancer is a leukemia, lymphoma or myeloma. 
     
     
         34 . The method according to  claim 20 , wherein the cancer is a neuroblastoma. 
     
     
         35 . The method according to  claim 20 , wherein the cancer is a malignant melanoma. 
     
     
         36 . The method according to  claim 20 , wherein the cancer is a carcinoma selected from the group consisting of breast, ovarian, prostate, lung, kidney, stomach, colorectal, liver and pancreatic carcinomas.